1887
  1. Home
  2. A-Z Publications
  3. Global Cardiology Science and Practice
  4. Volume 2015, Issue 2
  5. Article
Volume 2015, Issue 2
  • ISSN: 2305-7823
  • EISSN:

Abstract

Angina that is refractory to conventional medical therapy and revascularisation, remains challenging to manage and poses significant burden to patients. Elevated lipoprotein(a) [Lp(a)] has emerged as an important independent cardiovascular risk factor and predictor of adverse outcomes in atherosclerotic disease. The prevalence of raised Lp(a) amongst patients with refractory angina has not yet been defined. To establish the prevalence of raised [Lp(a)] >500 mg/L in patients with refractory angina. We conducted an epidemiological screening pilot study in 75 patients with refractory angina from a UK tertiary cardiac centre. We determined the proportion of the cohort with raised Lp(a) >500 mg/L using an isoform-insensitive method. In addition, a full fasting lipid profile (including: LDL cholesterol, HDL cholesterol, total cholesterol to HDL ratio and triglycerides) was obtained. Patients were also asked about the presence of conventional cardiovascular risk factors. Our study demonstrated that 60% of the 75 patients with refractory angina had raised Lp(a) levels of >500 mg/L. The median and inter-quartile range of Lp(a) values were 771 mg/L (162 mg/L,1260 mg/L) respectively. This high prevalence of raised Lp(a) detected in our cohort with refractory angina may suggest a causal role. Further research is necessary to confirm this association and prospective studies are needed to explore the potential therapeutic benefit of Lp(a) reduction in patients with refractory angina.

© 2015 Khan, Rhodes, Pottle, Banya, Smith, Kabir, Ilsely, Pennell, Barbir, licensee Bloomsbury Qatar Foundation Journals.
Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2015.28
2015-07-07
2024-04-20
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2015/2/gcsp.2015.28.html?itemId=/content/journals/10.5339/gcsp.2015.28&mimeType=html&fmt=ahah

References

  1. Kim MC, Kini A, Sharma SK. Refractory angina pectoris. Mechanism and therapeutic options. J Am Coll Cardiol. 2002; 39:6:923–934.
     [Google Scholar]
  2. Mannheimer C, Camici P, Chester MR, Collins A, DeJongste M, Eliasson T, Follath F, Hellemans I, Herlitz J, Lüscher T, Pasic M, Thelle D. The problem of chronic refractory angina; report from the ESC joint study group on the treatment of refractory angina. Eur Heart J. 2002; 23:5:355–370.
     [Google Scholar]
  3. DeJongste MJL, Tio RA, Foreman RD. Chronic therapeutically refractory angina pectoris. Heart. 2004; 90::225–230.
     [Google Scholar]
  4. Soran O. Treatment options for refractory angina pectoris: Enhanced external counterpulsation therapy. Curr Treat Options Cardiovasc Med. 2009; 11::54–60.
     [Google Scholar]
  5. Manchanda A, Aggarwal A, Aggarwal N, Soran O. Management of refractory angina pectoris. Cardiology Journal. 2011; 18:4:343–351.
     [Google Scholar]
  6. Berg K. A new serum type system in man: the Lp system. ActaPatholMicrobiolScand. 1963; 59::369–382.
     [Google Scholar]
  7. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest. 1994; 24::444–453.
     [Google Scholar]
  8. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000; 102:10:1082–1085.
     [Google Scholar]
  9. Solanki US, Kumar A. Lipoprotein(a) in essential hypertension patients. Indian Medical Gazette. 2013; Vol.CXLVII:No.8:292–295.
     [Google Scholar]
  10. Erqou S, Kaptoge S, Perry PL, Angelantonio ED, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and non-vascular mortality. JAMA. 2009; 302::412–423.
     [Google Scholar]
  11. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31::2844–2853.
     [Google Scholar]
  12. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009; 361:26:2518–2528.
     [Google Scholar]
  13. Bambauer R, Olbricht CJ, Schoeppe E. Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results. Ther Apher Dial. 1997; 1::242–248.
     [Google Scholar]
  14. Stephen Bohl S, Kassner U, Eckardt R, Utz W, Mueller-Nordhorn J, Busjahn A, Thomas HP, Abdel-Aty H, Klingel R, Marcovina S, Dietz R, Steinhagen-Thiessen E, Schulz-Menger J, Vogt A. Single Lipoprotein Apheresis Session Improves Cardiac Microvascular Function in Patients with Elevated Lipoprotein(a): Detection by Stress/Rest Perfusion Magnetic Resonance Imaging. TherApher Dial. 2009; 13::129–137.
     [Google Scholar]
  15. HPS2-THRIVE Collaborative Group. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New England Journal of Medicine. 2014; 371:3:203–212. doi:10.1056/NEJMoa1300955 .
     [Google Scholar]
  16. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huang F, Xue A, Albizem M, Scott R, Stein EA. Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of More Than 1,300 Patients in 4 Phase II Trials. J Am Coll Cardiol. 2014; 63:13:1278–1288.
     [Google Scholar]
  17. Merki E, Graham M, Taleb A, Leibundgut G, Yang X, Miller ER, Fu W, Mullick AE, Lee R, Willeit P, Crooke RM, Witztum JL, Tsimikas S. Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein(a) and Lipoprotein (a) in Transgenic Mice. J Am Coll Cardiol. 2011; 57::1611–1621.
     [Google Scholar]
  18. Borberg H. Comparison of different Lp(a) elimination techniques: A retrospective evaluation. Trans Apheres Sci. 2009; 41:1:61–65.
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2015.28
Loading
High prevalence of raised lipoprotein(a) in patients with refractory angina
Global Cardiology Science and Practice 2015, 28 (2015); https://doi.org/10.5339/gcsp.2015.28
/content/journals/10.5339/gcsp.2015.28
/content/journals/10.5339/gcsp.2015.28
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): Coronary artery disease, Lipoprotein (a), Refractory angina and Risk factors
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error